EN DE
Watch Aurora Cannabis Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Aurora Cannabis Inc (ACB) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Aurora Cannabis Inc stock $3.33, price $5.24, that is 36.5% below the price, quality 32 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Canada · ISIN CA05156X8504

AC Aurora Cannabis Inc logo Thin data Nov 8, 2026

Aurora Cannabis Inc

ACB · US
Very expensive, weak quality

Our calculation puts a fair price 36% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +5.6 %/yr in CAD)
Revenue last quarter 9% below a year ago.
Fair value $3.33 · Strongly overvalued
Quality 32/100
Loss-making · -38.3% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 6/100
Thin data
Watch Aurora Cannabis Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$85.00 $2.58 Fair Value $3.33 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $2.58 – $85.00 · fair‑value band $2.20 – $4.16 · the $5.24 price screens above the $3.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Aurora Cannabis in your weekly email

Every Wednesday you see whether Aurora Cannabis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Aurora Cannabis Inc., together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-derivative products in Canada and internationally. It operates through two segments, Canadian Cannabis and Plant Propagation.

Show moreShow less

The company offers pharmaceutical-grade cannabis products; medical and consumer cannabis products; and engages in the propagation of vegetables and floral plants.

It also provides dried and fresh cannabis, cannabis oils, trims, concentrates, ingestibles, capsules, vaporizers, edible cannabis, cannabis extracts, and cannabis topicals; and patient counseling and outreach services.

Its brand portfolio includes San Rafael '71, Greybeard, Drift, Daily Special, Being, CanniMed, MedReleaf, Aurora, and WMMC, as well as international brands include Pedanios, Bidiol, IndiMed, and CraftPlant. The company was founded in 2013 and is headquartered in Edmonton, Canada.

Stock analysis

Aurora Cannabis Inc (ACB) currently trades at $5.24, while our model-based Fair Value estimate is $3.33, 36% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $2.20 (bear) to $4.16 (bull), the price of $5.24 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Aurora Cannabis Inc reported revenue of C$321M in FY2026 versus C$221M in FY2022, a compound +9.8%/yr. Reported net income was −C$122M in FY2026.

Key figures

Market cap $345M Small · P/S ratio 1.10 · EPS (TTM) $−0.6100 · Net margin −38.0% · Return on equity −9.4% · Return on assets (EBIT) −15.9% (5-year average) · Operating margin −12.9% · Revenue (TTM) C$314M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (medium confidence).

What moves the price

The share trades about 6% below its 52-week high and 103% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −36%, ACB screens richer than that median.

Fair Value models

Bear $2.20 Fair Value $3.33 Bull $4.16
Price $5.24 · Downside -36.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $2.20 $3.33 $4.16 55
All 1 models by family
Asset-Based
NCAV (Graham) $2.20 $3.33 $4.16 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 13
How calm the share price moves, does not count
Price momentum 78
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 71
Distance to the 52-week high, does not count
New shares 31
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2021 (pandemic). Over 10 years: +71.8% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−115.3% (2021) → −50.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ACB screens overvalued: fair value 36% below the price. Compare with Merck KGaA →

Compare Aurora Cannabis Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −36.5% · Below median
Profitability
Return on assets −20.3% · Bottom 25%
Net margin (12 months) −38.3% · Bottom 25%
Operating margin (12 months) −12.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −8.8% · Below median
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.95× · Cheapest 25%
P/S (12 months) 1.55× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs ACB
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs ACB
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs ACB
Haleon plc HLN $9.14 $8.61 −6% vs ACB
Merck KGaA MRK €148.75 €109.18 −27% vs ACB
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs ACB
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs ACB
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs ACB
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs ACB
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs ACB

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aurora Cannabis Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Aurora Cannabis Inc Fair Value". https://www.fairvalue-calculator.com/stock/ACB

Frequently asked questions

Is Aurora Cannabis Inc (ACB) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $3.33 versus a price of $5.24, about 36% lower (overvalued).
What is the fair value of ACB?
Our model-based fair value for Aurora Cannabis Inc is $3.33 (as of Nov 8, 2026), built from audited fundamentals. The current price: $5.24.
What is the quality score of ACB?
Aurora Cannabis Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aurora Cannabis Inc (ACB)?
Our model-based price target is the fair value of $3.33 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $2.20, optimistic scenario $4.16. It is a calculation from audited fundamentals, not an analyst target.
What is the Aurora Cannabis Inc stock forecast for 2026?
Our models put fair value at $3.33, about 36% lower versus a price of $5.24 (overvalued). Cautious scenario $2.20, optimistic scenario $4.16. The calculation is refreshed regularly with new filings.
What is the revenue of Aurora Cannabis Inc (ACB)?
Aurora Cannabis Inc reported trailing-twelve-month revenue of about C$314M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Aurora Cannabis Inc (ACB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aurora Cannabis Inc it is $3.33 per share (as of Nov 8, 2026), against a price of $5.24. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Aurora Cannabis Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ACB trades above its calculated fair value: price $5.24, fair value $3.33, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ACB?
No. The price is what the market pays today ($5.24); the fair value is what the company's own numbers justify ($3.33). For Aurora Cannabis Inc the two are $1.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aurora Cannabis Inc worth?
The market values Aurora Cannabis Inc at about $345M (market capitalisation, as of Nov 8, 2026). Per share that is $5.24; our models calculate a fair value of $3.33 per share.
What do the bullish and bearish scenarios say about ACB?
Our models span a range for Aurora Cannabis Inc: cautious scenario $2.20, base $3.33, optimistic $4.16 per share (as of Nov 8, 2026, price $5.24). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aurora Cannabis Inc (ACB)?
Balance-sheet figures for Aurora Cannabis Inc (as of Nov 8, 2026): return on equity −9.4%, debt of 0.08 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ACB from its 52-week high?
Aurora Cannabis Inc trades at $5.24, about 6% below its 52-week high of $5.57 and 103% above the low of $2.58 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $3.33 is for.
Which stocks are comparable to Aurora Cannabis Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aurora Cannabis Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $5.24, calculated fair value $3.33 (−36%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ACB calculated?
We run Aurora Cannabis Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $3.33 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Aurora Cannabis Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aurora Cannabis Inc (ACB)?
The closing price on Nov 6, 2026 was $5.24. Our model-based fair value is $3.33, about 36% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aurora Cannabis Inc right now?
The price sits above even our optimistic bull case ($4.16). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($2.20 to $4.16) leaves room in how you read the outcome.

Key figures of Aurora Cannabis Inc

How large is the market capitalisation of Aurora Cannabis Inc (ACB)?
The market capitalisation of Aurora Cannabis Inc is $345M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aurora Cannabis Inc (ACB)?
The price-to-sales ratio of Aurora Cannabis Inc is 1.10 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aurora Cannabis Inc (ACB)?
Earnings per share at Aurora Cannabis Inc are $−0.6100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aurora Cannabis Inc (ACB)?
The net margin of Aurora Cannabis Inc is −38.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aurora Cannabis Inc (ACB)?
The return on equity (ROE) of Aurora Cannabis Inc is −9.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aurora Cannabis Inc (ACB)?
On an EBIT basis the return on assets of Aurora Cannabis Inc is −15.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aurora Cannabis Inc (ACB)?
The operating margin of Aurora Cannabis Inc is −12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aurora Cannabis Inc (ACB)?
Revenue at Aurora Cannabis Inc is growing −8.8% versus a year earlier (3y avg +12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aurora Cannabis Inc (ACB)?
Earnings per share at Aurora Cannabis Inc are growing −94.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aurora Cannabis Inc (ACB) generate?
The free cash flow of Aurora Cannabis Inc is −C$36.1M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Aurora Cannabis Inc (ACB) hold?
Aurora Cannabis Inc holds more cash than debt, C$88.9M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Aurora Cannabis Inc in the live analysis

One click puts Aurora Cannabis Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.